Turn Therapeutics (NASDAQ:TTRX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Turn Therapeutics (NASDAQ:TTRX) from a hold rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other research analysts have also recently weighed in on the stock. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Turn Therapeutics Trading Down 2.7%

NASDAQ:TTRX opened at $9.80 on Friday. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market capitalization of $291.94 million and a PE ratio of -33.79. The business’s 50-day simple moving average is $9.17 and its 200-day simple moving average is $5.94.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Sell-side analysts expect that Turn Therapeutics will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new position in shares of Turn Therapeutics during the 2nd quarter worth about $119,000. Bank of America Corp DE acquired a new stake in shares of Turn Therapeutics in the second quarter valued at about $103,000. Ieq Capital LLC bought a new stake in Turn Therapeutics during the second quarter worth about $1,660,000. BlackRock Inc. bought a new stake in Turn Therapeutics during the second quarter worth about $282,000. Finally, Bridgewater Advisors Inc. acquired a new position in Turn Therapeutics during the second quarter valued at approximately $242,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.